Stocks · News reference

8-K filing — Summit Therapeutics Inc. (SMMT)

Sep 15, 2026, 12:44 PMSEC EDGAR

Filed: 2026-09-15 AccNo: 0001599298-26-000081 Size: 2 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 15, 2026, 10:19 AMBenzinga Newsdesk
Summit Therapeutics Presents Updated Overall Survival Results From Global Phase III HARMIONi Clinical Trial Of Ivonescimab At The International Association For The Study Of Lung Cancer Conference; Sustained OS Improvement Seen With Longer Follow-Up In Western Patients, Consistent Across Geographic Regions; No New Safety Signals Observed
Updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab were presented today at the
SMMT
BenzingaSep 14, 2026, 4:53 PMVandana Singh
Why Is Summit Therapeutics Stock Gaining Monday?
Summit partner Akeso reports 30.8-month median OS for ivonescimab vs 22.6 for pembrolizumab in lung cancer trial. SMMT up over 6%.
SMMT
BenzingaSep 14, 2026, 5:46 AMBenzinga Newsdesk
Reported Sunday, Ivonescimab Monotherapy Reduces Risk Of Death By 27% Versus Pembrolizumab In PD-L1-Positive Advanced NSCLC, Akeso's HARMONi-2 Study Shows
Ivonescimab Reduced the Risk of Death by 27% Compared to PembrolizumabHARMONi-2 Demonstrated an Improvement in Median Overall Survival of 8.2 MonthsPD-L1 High Expression Subgroup: Hazard Ratio = 0.58Summit is Conducting
SMMT